Compass Pathways (CMPS) rose premarket after partnering with Osmind to educate over 1,000 US clinics on its COMP360 therapy. The collaboration prepares providers for potential FDA approval. This follows a 42% rally on Monday and Trump's executive order to fast-track psychedelic drug reviews.